Neovascular age-related macular degeneration research hub
10 indexed studies · 3 currently recruiting
- ongoing, recruitingPhase III and phase IV (Integrated)
Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)
This study looks at a new way to use an existing medicine, aflibercept 8mg, for an eye condition called wet age-related macular degeneration (wet AMD). It aims to see if longer times between injections are possible for people already treated with other medicines.
Austria - recruitingPHASE3
Extension Study for the Port Delivery System With Ranibizumab (Portal)
This study looks at a long-term eye implant to treat 'wet' age-related macular degeneration (nAMD). It checks the safety of the implant and how well it works over time in people who have been in previous studies. It also explores ways to manage potential side effects.
United States · Argentina · Australia - active not recruitingPHASE2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
This study, called LUNA, is testing a new gene therapy called ADVM-022 for 'wet' Age-related Macular Degeneration (nAMD). It aims to reduce the need for frequent eye injections by delivering a sustained treatment with a single injection, hoping to improve vision. We're looking at its safety and how well it works.
United States · France · United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Long-term Follow-Up Study to Evaluate the Safety and Efficacy of RGX-314 Following Subretinal Administration in Participants with Neovascular Age-related Macular Degeneration and Fellow Eye Treatment Substudy
This study is looking long-term at the safety and how well a new treatment, Surabgene Lomparvovec (ABBV-RGX-314), works for wet age-related macular degeneration (nAMD). It's given as a single injection into the eye to see if it can help improve or maintain vision and reduce the need for repeat injections.
Italy · Hungary · France - recruitingPHASE3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
This study looks at a new gene therapy, Surabgene Lomparvovec, for 'wet' age-related macular degeneration (nAMD). It aims to see if it's safe and effective in reducing the need for frequent eye injections and protecting vision in adults.
United States · Austria · Belgium - ongoing, recruitingPhase III and phase IV (Integrated)
Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)
This study compares two treatments, Vabysmo and Eylea, for a serious eye condition called 'wet' age-related macular degeneration (AMD). The aim is to see which treatment can keep the eye healthy and vision stable for longer, with fewer injections.
Austria - recruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
Austria · Czechia · Denmark - active not recruitingPHASE1, PHASE2
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
This study is looking at a new one-time treatment called SAR402663 for a common eye condition called 'wet' age-related macular degeneration (AMD). Researchers want to see if it's safe and helps improve or maintain vision. It's a key early stage of clinical research.
United States · United Kingdom - active not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
This study looks at how well certain eye medicines from Roche work for conditions like wet macular degeneration and diabetic eye disease in real patients. It's about understanding long-term results and why doctors choose specific treatments, without changing how patients are usually cared for.
United States · Argentina · Australia - ongoing, recruitingTherapeutic use (Phase IV)
Two initial faricimab loading doses in treatment-naive neovascular AMD
This study looks at a new way to treat wet age-related macular degeneration (AMD) using a medicine called Vabysmo. Doctors want to see if giving two starting doses helps control the disease quickly, checking patients after 8 weeks to see how well it's working.
Austria